Ozempic’s Wild Card: Why Some Melt, Others Stall

Woman sitting on floor covering face beside a bathroom scale
Photo: Tero Vesalainen / Shutterstock

Not every patient on Ozempic or Wegovy loses weight the same way, and new research shows the body often fights back against the drug’s effects.

Quick Take

  • A 115-person study found average weight loss of 10% at seven months and 13% at one year, but results varied widely between patients
  • Body scans showed fat mass dropping sharply while lean muscle mass fell early, then leveled off
  • Resting energy use dropped at seven months but rose again by month 12, confusing simple “slowing metabolism” explanations
  • Across major semaglutide trials, 10% to 17% of patients lost less than 5% of their weight, while up to 40% lost more than 20%

Real-World Results Show Wide Swings Between Patients

A prospective study called SEMALEAN tracked 115 adults with obesity from February 2022 through November 2024. Researchers measured weight, body composition, muscle strength, and resting energy use at the start, seven months, and 12 months. Average body weight dropped 10% at seven months and 13% at one year. Fifty-nine percent of participants lost at least 10% of their starting weight.

That means roughly four in ten participants fell short of the 10% mark, even while taking the same medication under supervised conditions. Averages hide that spread. A treatment that moves the needle by double digits for some patients barely budges the scale for others, and the reasons behind that gap are still being worked out by researchers.

The Scale Doesn’t Tell the Whole Story

SEMALEAN researchers used DXA body scans, not just a bathroom scale, to track what was actually disappearing. Fat mass fell about 14% at seven months and nearly 19% by one year. Lean mass dropped by roughly three kilograms early in treatment, then stabilized. As total weight loss increased, the ratio of lean mass to fat mass actually improved, suggesting the body preserved more muscle relative to fat over time.

This distinction matters because two patients who lose the same number of pounds can have very different outcomes underneath the surface. One may shed mostly fat and keep muscle function intact. Another may lose more lean tissue, which can affect strength and long-term metabolic health. Weight loss percentages alone cannot capture that difference without body composition testing.

Metabolism Shifts in Ways That Don’t Fit a Simple Story

Resting energy expenditure, the calories a body burns at rest, dropped by 244 kilocalories per day at the seven-month mark in the SEMALEAN cohort. That decline is consistent with what happens when any body gets smaller, since smaller bodies generally need fewer calories. But by 12 months, resting energy use increased significantly again, even after adjusting for lean mass.

An earlier 2017 controlled study found a similar pattern. Resting metabolic rate was lower after 12 weeks of semaglutide, but once researchers adjusted for lean body mass, the difference was no longer statistically significant. A ScienceDaily summary from November 2026 described the research on resting energy use as “neutral or inconclusive,” calling it “an open question for exploration” rather than a settled matter.

Why Some Patients Respond Far Less Than Others

Separate research has tried to identify who is most likely to see smaller results. Patients with type 2 diabetes tend to lose significantly less weight on semaglutide than those without it. Women tend to lose more weight than men, by about six percentage points on average, according to a review of predictor studies.

Across the larger STEP trial program for semaglutide, the spread of outcomes was dramatic. Between 10% and 17% of participants lost less than 5% of their starting weight, essentially minimal response. Meanwhile, 32% to 40% lost more than 20%, earning the label “super responders”. That split shows obesity medication, like most treatments, does not work the same way in every body.

What Still Needs to Be Proven

Animal research adds another layer. A study in minipigs found semaglutide helped prevent some of the energy-conserving changes that normally happen during diet-based calorie restriction, suggesting the drug may do more than just suppress appetite. Separate laboratory work has also found that brain cells involved in appetite signaling respond in highly varied ways at the cellular level, hinting at a biological basis for why people differ.

None of this proves exactly why some patients plateau early or respond weakly. What the evidence does show is that semaglutide’s effects go beyond the number on a scale, touching fat mass, lean mass, and resting metabolism in ways that shift over time. Larger, longer studies with direct metabolic testing will be needed to pin down which patients are most likely to need a different approach.

Sources:

sciencedaily.com, pmc.ncbi.nlm.nih.gov, agupubs.onlinelibrary.wiley.com, link.springer.com, frontiersin.org, researchprofiles.ku.dk